Alternating sequential chemotherapy with high-dose ifosfamide and doxorubicin/cyclophosphamide for adult non-small round cell soft tissue sarcomas

Akira Kawai, Toru Umeda, Takuro Wada, Koichiro Ihara, Kazuo Isu, Satoshi Abe, Takeshi Ishii, Hideshi Sugiura, Nobuhito Araki, Toshihumi Ozaki, Hiroo Yabe, Tadashi Hasegawa, Shoichiro Tsugane, Yasuo Beppu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Doxorubicin and ifosfamide are the two most active agents used to treat soft tissue sarcomas. However, because of their overlapping side effects, concurrent administration to achieve optimal doses of each agent is difficult. We therefore conducted a Phase II trial to investigate the efficacy and feasibility of a novel alternating sequential chemotherapy regimen consisting of high dose ifosfamide and doxorubicin/cyclophosphamide in advanced adult non-small round cell soft tissue sarcomas. Adult patients with non-small round cell soft tissue sarcomas were enrolled. The treatment consisted of four sequential courses of chemotherapy that was planned for every 3 weeks. Cycles 1 and 3 consisted of ifosfamide (14 g/m2), and cycles 2 and 4 consisted of doxorubicin (60 mg/m2) and cyclophosphamide (1200 mg/m 2). Forty-two patients (median age 47 years) were enrolled. Of the 36 assessable patients, 1 complete response and 16 partial responses were observed, for a response rate of 47.2%. Responses were observed in 57% of patients who had received no previous chemotherapy and 13% of those who had previously undergone chemotherapy. Grade 3-4 neutropenia was observed during 70% of all cycles. Sequential administration of high-dose ifosfamide and doxorubicin/cyclophosphamide has promising activity with manageable side effects in patients with advanced adult non-small round cell soft tissue sarcomas.

Original languageEnglish
Pages (from-to)258-263
Number of pages6
JournalJournal of Orthopaedic Science
Volume10
Issue number3
DOIs
Publication statusPublished - May 2005

Fingerprint

Ifosfamide
Sarcoma
Doxorubicin
Cyclophosphamide
Drug Therapy
Neutropenia

ASJC Scopus subject areas

  • Surgery

Cite this

Alternating sequential chemotherapy with high-dose ifosfamide and doxorubicin/cyclophosphamide for adult non-small round cell soft tissue sarcomas. / Kawai, Akira; Umeda, Toru; Wada, Takuro; Ihara, Koichiro; Isu, Kazuo; Abe, Satoshi; Ishii, Takeshi; Sugiura, Hideshi; Araki, Nobuhito; Ozaki, Toshihumi; Yabe, Hiroo; Hasegawa, Tadashi; Tsugane, Shoichiro; Beppu, Yasuo.

In: Journal of Orthopaedic Science, Vol. 10, No. 3, 05.2005, p. 258-263.

Research output: Contribution to journalArticle

Kawai, A, Umeda, T, Wada, T, Ihara, K, Isu, K, Abe, S, Ishii, T, Sugiura, H, Araki, N, Ozaki, T, Yabe, H, Hasegawa, T, Tsugane, S & Beppu, Y 2005, 'Alternating sequential chemotherapy with high-dose ifosfamide and doxorubicin/cyclophosphamide for adult non-small round cell soft tissue sarcomas', Journal of Orthopaedic Science, vol. 10, no. 3, pp. 258-263. https://doi.org/10.1007/s00776-005-0899-3
Kawai, Akira ; Umeda, Toru ; Wada, Takuro ; Ihara, Koichiro ; Isu, Kazuo ; Abe, Satoshi ; Ishii, Takeshi ; Sugiura, Hideshi ; Araki, Nobuhito ; Ozaki, Toshihumi ; Yabe, Hiroo ; Hasegawa, Tadashi ; Tsugane, Shoichiro ; Beppu, Yasuo. / Alternating sequential chemotherapy with high-dose ifosfamide and doxorubicin/cyclophosphamide for adult non-small round cell soft tissue sarcomas. In: Journal of Orthopaedic Science. 2005 ; Vol. 10, No. 3. pp. 258-263.
@article{7eca47ba79f142929da7e84a623c6f32,
title = "Alternating sequential chemotherapy with high-dose ifosfamide and doxorubicin/cyclophosphamide for adult non-small round cell soft tissue sarcomas",
abstract = "Doxorubicin and ifosfamide are the two most active agents used to treat soft tissue sarcomas. However, because of their overlapping side effects, concurrent administration to achieve optimal doses of each agent is difficult. We therefore conducted a Phase II trial to investigate the efficacy and feasibility of a novel alternating sequential chemotherapy regimen consisting of high dose ifosfamide and doxorubicin/cyclophosphamide in advanced adult non-small round cell soft tissue sarcomas. Adult patients with non-small round cell soft tissue sarcomas were enrolled. The treatment consisted of four sequential courses of chemotherapy that was planned for every 3 weeks. Cycles 1 and 3 consisted of ifosfamide (14 g/m2), and cycles 2 and 4 consisted of doxorubicin (60 mg/m2) and cyclophosphamide (1200 mg/m 2). Forty-two patients (median age 47 years) were enrolled. Of the 36 assessable patients, 1 complete response and 16 partial responses were observed, for a response rate of 47.2{\%}. Responses were observed in 57{\%} of patients who had received no previous chemotherapy and 13{\%} of those who had previously undergone chemotherapy. Grade 3-4 neutropenia was observed during 70{\%} of all cycles. Sequential administration of high-dose ifosfamide and doxorubicin/cyclophosphamide has promising activity with manageable side effects in patients with advanced adult non-small round cell soft tissue sarcomas.",
author = "Akira Kawai and Toru Umeda and Takuro Wada and Koichiro Ihara and Kazuo Isu and Satoshi Abe and Takeshi Ishii and Hideshi Sugiura and Nobuhito Araki and Toshihumi Ozaki and Hiroo Yabe and Tadashi Hasegawa and Shoichiro Tsugane and Yasuo Beppu",
year = "2005",
month = "5",
doi = "10.1007/s00776-005-0899-3",
language = "English",
volume = "10",
pages = "258--263",
journal = "Journal of Orthopaedic Science",
issn = "0949-2658",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Alternating sequential chemotherapy with high-dose ifosfamide and doxorubicin/cyclophosphamide for adult non-small round cell soft tissue sarcomas

AU - Kawai, Akira

AU - Umeda, Toru

AU - Wada, Takuro

AU - Ihara, Koichiro

AU - Isu, Kazuo

AU - Abe, Satoshi

AU - Ishii, Takeshi

AU - Sugiura, Hideshi

AU - Araki, Nobuhito

AU - Ozaki, Toshihumi

AU - Yabe, Hiroo

AU - Hasegawa, Tadashi

AU - Tsugane, Shoichiro

AU - Beppu, Yasuo

PY - 2005/5

Y1 - 2005/5

N2 - Doxorubicin and ifosfamide are the two most active agents used to treat soft tissue sarcomas. However, because of their overlapping side effects, concurrent administration to achieve optimal doses of each agent is difficult. We therefore conducted a Phase II trial to investigate the efficacy and feasibility of a novel alternating sequential chemotherapy regimen consisting of high dose ifosfamide and doxorubicin/cyclophosphamide in advanced adult non-small round cell soft tissue sarcomas. Adult patients with non-small round cell soft tissue sarcomas were enrolled. The treatment consisted of four sequential courses of chemotherapy that was planned for every 3 weeks. Cycles 1 and 3 consisted of ifosfamide (14 g/m2), and cycles 2 and 4 consisted of doxorubicin (60 mg/m2) and cyclophosphamide (1200 mg/m 2). Forty-two patients (median age 47 years) were enrolled. Of the 36 assessable patients, 1 complete response and 16 partial responses were observed, for a response rate of 47.2%. Responses were observed in 57% of patients who had received no previous chemotherapy and 13% of those who had previously undergone chemotherapy. Grade 3-4 neutropenia was observed during 70% of all cycles. Sequential administration of high-dose ifosfamide and doxorubicin/cyclophosphamide has promising activity with manageable side effects in patients with advanced adult non-small round cell soft tissue sarcomas.

AB - Doxorubicin and ifosfamide are the two most active agents used to treat soft tissue sarcomas. However, because of their overlapping side effects, concurrent administration to achieve optimal doses of each agent is difficult. We therefore conducted a Phase II trial to investigate the efficacy and feasibility of a novel alternating sequential chemotherapy regimen consisting of high dose ifosfamide and doxorubicin/cyclophosphamide in advanced adult non-small round cell soft tissue sarcomas. Adult patients with non-small round cell soft tissue sarcomas were enrolled. The treatment consisted of four sequential courses of chemotherapy that was planned for every 3 weeks. Cycles 1 and 3 consisted of ifosfamide (14 g/m2), and cycles 2 and 4 consisted of doxorubicin (60 mg/m2) and cyclophosphamide (1200 mg/m 2). Forty-two patients (median age 47 years) were enrolled. Of the 36 assessable patients, 1 complete response and 16 partial responses were observed, for a response rate of 47.2%. Responses were observed in 57% of patients who had received no previous chemotherapy and 13% of those who had previously undergone chemotherapy. Grade 3-4 neutropenia was observed during 70% of all cycles. Sequential administration of high-dose ifosfamide and doxorubicin/cyclophosphamide has promising activity with manageable side effects in patients with advanced adult non-small round cell soft tissue sarcomas.

UR - http://www.scopus.com/inward/record.url?scp=21044442548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21044442548&partnerID=8YFLogxK

U2 - 10.1007/s00776-005-0899-3

DO - 10.1007/s00776-005-0899-3

M3 - Article

VL - 10

SP - 258

EP - 263

JO - Journal of Orthopaedic Science

JF - Journal of Orthopaedic Science

SN - 0949-2658

IS - 3

ER -